Meds A-Z

Atipamezole Hydrochloride

Detailed information about Atipamezole Hydrochloride

Official label facts Owner quick guide first Marketing clearly labeled

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Reviewed / Updated / Sources

Reviewed: Not available

Updated: February 12, 2026, 10:44 PM UTC

Sources:

FDA application profile · official_label
FDA application profile · official_label
Medication usage source · fda_animal_drugs
Cropamezole™ · official_label
openFDA case USA-USFDACVM-2025-US-049334 · adverse_reaction

Pet Owner Quick Guide

Start here first for the simple next-step summary.

Used for:

For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs.

What to watch for:

For intramuscular use only
Not recommended for use in pregnant or lactating animals, or animals intended for breeding
Atipamezole has not been evaluated in breeding animals
very low energy (1 reports)
Reddening of the skin (1 reports)
Pyuria (1 reports)

When to call the vet:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.
Facial swelling or hives.
Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Safety & side effects

What to watch:

For intramuscular use only
Not recommended for use in pregnant or lactating animals, or animals intended for breeding
Atipamezole has not been evaluated in breeding animals
very low energy
Reddening of the skin

Most reported reactions:

Tiredness (lethargy) (1 reports)
Reddening of the skin (1 reports)
Pyuria (1 reports)

When to call your vet:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Data freshness: source data appears current.

Latest refresh: Mar 21, 2026, 10:03 a.m.

Data freshness

Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Mar 3, 2026, 11:00 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Mar 21, 2026, 10:03 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:21 AM UTC

Image coming soon

Atipamezole Hydrochloride

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Both

Manufacturer: Not available (source)

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both

Manufacturer: Not available

Form: Liquid (Solution), Sterile Injectable Solution

Identifiers:

ANADA: 200624 ANADA: 200753 ANADA: 200772 ANADA: 200838 NADA: 141033 NDC Package: 11695-7020-1 NDC Package: 15914-008-01 NDC Package: 43744-021-01 NDC Package: 46066-109-13 NDC Package: 54771-6293-1 NDC Package: 64189-0001-0 NDC Package: 64189-0001-1 NDC Package: 68504-007-01 NDC Package: 69043-039-10 NDC Package: 86136-106-31 NDC Package: 86136-115-31 NDC Package: 86136-151-31 NDC Package: 86197-002-01 NDC Package: 86197-002-02 NDC Product: 11695

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200838 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200772 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

For intramuscular use only. Not recommended for use in pregnant or lactating animals, or animals intended for breeding. Atipamezole has not been evaluated in breeding animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

High: For intramuscular use only. Not recommended for use in pregnant or lactating animals, or animals intended for breeding. Atipamezole has not been evaluated in breeding animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals

Reported cases

Serious reports

Species represented

Grouped by Body System

Digestive (1) · Loss of appetite Neurologic (2) · Tiredness (lethargy), Head tremor Behavior (2) · Biting -aggression, Behavioral disorder (unspecified) Effectiveness (1) · Lack of efficacy - NOS Other (26) · Reddening of the skin, Pyuria, Pain NOS

Most Reported Reactions

Body system	Cases	Species	Serious cases
Neurologic	1	Dog	1
Other	1	Dog	1
Other	1	Dog	1
Other	1	Cat	1
Other	1	Cat	1
Other	1	Cat	1
Other	1	Cat	1
Other	1	Cat	1

Species coverage: Cat (17) Dog (15)

View detailed reaction table

Body system	Species	Seriousness	Frequency	Reports
Neurologic	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Digestive	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Effectiveness	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Neurologic	Cat	Non-serious	-	1
Other	Cat	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Behavior	Cat	Non-serious	-	1
Behavior	Cat	Non-serious	-	1
Other	Cat	Serious	-	1

Source metadata:

https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-049334

Documents

Owner handouts and official technical documents are grouped for faster access.

Owner handouts (0)

No owner handouts linked yet.

Official label / PI (0)

No official label or package insert links yet.

SPL (5)

Atipamezole Hydrochloride Injection · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/18406/Atipamezole%20Hydrochloride%20Injection
CONTRASED™ · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/15345/CONTRASED%E2%84%A2
Cropamezole™ · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/14481/Cropamezole%E2%84%A2
REVERTIDINE™ · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/3416/REVERTIDINE%E2%84%A2
Antisedan® · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1833/Antisedan%C2%AE

FOI (6)

FOI Summary oA 200-838 Approved February 6, 2026.pdf · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/18046
FOI Summary oA 200-772 Approved March 1, 2024.pdf · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/15091
FOI Summary oA 200-753 Approved July 11, 2023.pdf · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/14244
FOI Summary oA 200-624 Approved July 2, 2018.pdf · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/3881
ucm116099.pdf · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/563
UCM487819.pdf · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/562

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/18046 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/18406/Atipamezole%20Hydrochloride%20Injection · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/15091 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/15345/CONTRASED%E2%84%A2 · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/14244 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/14481/Cropamezole%E2%84%A2 · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/3881 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/3416/REVERTIDINE%E2%84%A2 · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/563 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/562 · document · FOI

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness

Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Mar 3, 2026, 11:00 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Mar 21, 2026, 10:03 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Feb 9, 2026, 3:21 AM UTC

Official (FDA)

Identity: Generic ingredient • FDA branded products available

Official FDA brands: Antisedan® Atipamezole Hydrochloride Injection CONTRASED™ Cropamezole™ REVERTIDINE™

Case-reported brands (openFDA): MSK

Catalog species: Both • FDA-labeled species: Dog

Rx/OTC: RX

Form/route: Liquid (Solution), Sterile Injectable Solution • Intramuscular

Applications: ANADA 200-838 • ANADA 200-772 • ANADA 200-753 • ANADA 200-624 • NADA 141-033

Documents: 6 (FOI: 6) • SPL: 5 • Label highlights • Official documents

Safety (openFDA)

Top reactions: Dog 22 • Cat 14 • View

Case summaries: 10 (showing 8) • View

openFDA reports are unverified and do not prove causation.

Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points

For intramuscular use only. Not recommended for use in pregnant or lactating animals, or animals intended for breeding. Atipamezole has not been evaluated in breeding animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)

Top reaction signals

Tiredness (lethargy) (1) Reddening of the skin (1) Pyuria (1) Pain NOS (1) Overdose (1) Open mouth breathing (1) Not eating (1) Medication error NOS (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers

Package NDC	Product NDC	Status
11695-7020-1	11695	-
15914-008-01	15914	-
43744-021-01	43744	-
46066-109-13	46066	-
54771-6293-1	54771	-
64189-0001-0	64189	-
64189-0001-1	64189	-
68504-007-01	68504	-
69043-039-10	69043	-
86136-106-31	86136	-
86136-115-31	86136	-
86136-151-31	86136	-
86197-002-01	86197	-
86197-002-02	86197	-

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

FOI Summary oA 200-838 Approved February 6, 2026.pdf • FOI summary • Official • March 2, 2026
FDA FOI summary for application 200838
FOI Summary oA 200-772 Approved March 1, 2024.pdf • FOI summary • Official • Nov. 26, 2024
FDA FOI summary for application 200772
FOI Summary oA 200-753 Approved July 11, 2023.pdf • FOI summary • Official • Aug. 1, 2023
FDA FOI summary for application 200753
FOI Summary oA 200-624 Approved July 2, 2018.pdf • FOI summary • Official • Aug. 2, 2018
FDA FOI summary for application 200624
UCM487819.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 141033
ucm116099.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 141033

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 9 Clinical 0 Manufacturer 0 Marketing 0

Current Field Facts

contraindications: For intramuscular use only. Not recommended for use in pregnant or lactating animals, or animals intended for breeding. Atipamezole has not been evaluated in b… (Official, 2026-02-12)
side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Vomiting, INEFFECTIVE, REVERSAL, Bradycardia, Death, Diarrhoea. (Official, 2026-02-12)
usage: For reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride or medetomidine hydrochloride. For the reversal of the sedative and analges… (Official, 2026-02-12)

Recent Revisions

side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product	Sponsor	Application	Status	Published
Atipamezole Hydrochloride Injection RX Atipamezole Hydrochloride Sterile Injectable Solution • Intramuscular Label highlights Official documents	Felix Pharmaceuticals Pvt. Ltd.	ANADA 200-838	Approved	Mar 2, 2026
CONTRASED™ RX Atipamezole Hydrochloride Sterile Injectable Solution • Intramuscular Label highlights Official documents	Parnell Technologies Pty. Ltd.	ANADA 200-772	Approved	Nov 26, 2024
Cropamezole™ RX Atipamezole Hydrochloride Sterile Injectable Solution • Intramuscular Label highlights Official documents	Cronus Pharma Specialities India Private Ltd.	ANADA 200-753	Approved	Aug 1, 2023
REVERTIDINE™ RX Atipamezole Hydrochloride Sterile Injectable Solution • Intramuscular Label highlights Official documents	Modern Veterinary Therapeutics, LLC	ANADA 200-624	Approved	Aug 2, 2018
Antisedan® RX Atipamezole Hydrochloride Liquid (Solution) • Intramuscular Label highlights Official documents	Orion Corp.	NADA 141-033	Approved	Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications

5.0 mg atipamezole hydrochloride/mL

Dogs

Indication

For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs.

Dosage

Administer 3,750 mcg/m2 intramuscularly for the reversal of intravenous dexmedetomidine hydrochloride or medetomidine hydrochloride and 5,000 mcg/m2 intramuscularly for the reversal of intramuscular dexmedetomidine hydrochloride or medetomidine hydrochloride.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

5 mg/mL

Dogs

Indication

For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs.

Dosage

Administer intramuscularly (IM) for reversal of sedation and analgesia regardless of the route used for dexmedetomidine hydrochloride or medetomidine hydrochloride. The atipamezole dose for the reversal of intravenous dexmedetomidine hydrochloride or medetomidine hydrochloride is 3750 mcg/m2. The atipamezole dose for the reversal of IM dexmedetomidine hydrochloride or medetomidine hydrochloride is 5000 mcg/m2.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

5 mg/mL

Dogs

Indication

For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs.

Dosage

Administer 3750 mcg/m2 intramuscularly for the reversal of intravenous dexmedetomidine hydrochloride or medetomidine hydrochloride and 5000 mcg/m2 intramuscularly for the reversal of intramuscular dexmedetomidine hydrochloride or medetomidine hydrochloride.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

5.0 mg/mL

Dogs

Indication

For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs.

Dosage

REVERTIDINE™ is administered intramuscularly (IM) for reversal of sedation and analgesia regardless of the route used for dexmedetomidine or medetomidine. The atipamezole dose for the reversal of IV dexmedetomidine or medetomidine is 3750 mcg/m2.

The atipamezole dose for the reversal of IM dexmedetomidine or medetomidine is 5000 mcg/m2.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each milliliter of sterile injectable solution contains 5.0 milligrams of atipamezole hydrochloride.

Dogs

Indication

For reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride or medetomidine hydrochloride.

Dosage

The atipamezole dose for the reversal of intravenous (IV) DEXDOMITOR (dexmedetomidine hydrochloride), or DOMITOR (medetomidine hydrochloride) is 3750 mcg/m2. The atipamezole dose for the reversal of intramuscular (IM) DEXDOMITOR (dexmedetomidine hydrochloride), or DOMITOR (medetomidine hydrochloride) is 5000 mcg/m2.

Limitations

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents

FOI FOI Summary oA 200-838 Approved February 6, 2026.pdf

Summary

For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs.

SPL Packages

Atipamezole Hydrochloride Injection (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI FOI Summary oA 200-772 Approved March 1, 2024.pdf

Summary

For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs.

SPL Packages

CONTRASED™ (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI FOI Summary oA 200-753 Approved July 11, 2023.pdf

Summary

For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs.

SPL Packages

Cropamezole™ (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI FOI Summary oA 200-624 Approved July 2, 2018.pdf

Summary

For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs.

SPL Packages

REVERTIDINE™ (ZIP)

FDA page: Open in Animal Drugs @ FDA

Documents

FOI ucm116099.pdf

Summary

An additional indication for the reversal of the sedative and analgesic effects of DEXDOMITOR (dexmedetomidine hydrochloride).
FOI UCM487819.pdf

Summary

ANTISEDAN ® is indicated for the reversal of the clinical effects of the sedative and analgesic agent, DOMITOR® (medetomidine hydrochloride), in dogs.

SPL Packages

Antisedan® (ZIP)

FDA page: Open in Animal Drugs @ FDA

Usage

For reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride or medetomidine hydrochloride. For the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride, and medetomidine hydrochloride in dogs.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive

Loss of appetite (1) • Dog

Showing top 5 for Digestive.

Neurologic

Tiredness (1) • Dog Head tremor (1) • Cat

Showing top 5 for Neurologic.

Behavior

Biting -aggression (1) • Cat Behavioral disorder (1) • Cat

Showing top 5 for Behavior.

Effectiveness

Lack of efficacy - NOS (1) • Dog

Showing top 5 for Effectiveness.

Other

Reddening of the skin (1) • Dog Pyuria (1) • Dog Pain NOS (1) • Cat Overdose (1) • Cat Open mouth breathing (1) • Cat

Show more (21)

Not sleeping (1) • Cat Not eating (1) • Cat Medication error NOS (1) • Cat Lymphopenia (1) • Dog Localised pain NOS (1) • Dog Limb amputation (1) • Cat Leucopenia NOS (1) • Dog Intervertebral disc disease (1) • Dog Intentional misuse (1) • Cat Injection site sarcoma (1) • Cat Injection site lump (1) • Cat Increased heart rate (1) • Cat Heart block NOS (1) • Dog Head bobbing (1) • Cat Haematuria (1) • Dog Faecal incontinence (1) • Dog Extra dose(s) administered (1) • Cat Excessive chewing, licking and/or grooming (1) • Dog Decreased heart rate (1) • Dog Burn (1) • Dog Abnormal radiograph finding (1) • Cat

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, ['Hound (unspecified)', 'Dog (unknown)'], Female, 2.9 year, 18.824 kilogram • Drug: MSK, Solution, Intravenous • Reactions: Ventricular arrhythmia, Underdose, Medication error NOS, Lack of efficacy - NOS • Outcome: Recovered/Normal

Report ID: USA-USFDACVM-2025-US-056091
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 2.90 Year
Weight: 18.824 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Intravenous
Form: Solution

Reactions Reported:

Ventricular arrhythmia Underdose Medication error NOS Lack of efficacy - NOS

Outcomes: Recovered/Normal

Cat, Domestic Shorthair, Female, 10 month, 3.629 kilogram • Drug: MSK, Solution, Intramuscular, Dose: 0.50 mL per animal • Reactions: Shaking, Overdose, Medication error NOS, Increased heart rate, Intentional misuse • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-054487
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 10.00 Month
Weight: 3.629 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Intramuscular
Form: Solution
Dose: 0.50 mL per animal

Reactions Reported:

Shaking Overdose Medication error NOS Increased heart rate Intentional misuse

Outcomes: Ongoing

Dog, ['Dachshund - Standard Long-haired', 'Dog (unknown)'], Female, 12 year, 5.942 kilogram • Drug: MSK, Solution, Intramuscular, Dose: 0.20 mL per animal • Reactions: Localised pain NOS, Intervertebral disc disease, Excessive chewing, licking and/or grooming, Skin necrosis, Reddening of the skin… • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-054276
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 12.00 Year
Weight: 5.942 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Intramuscular
Form: Solution
Dose: 0.20 mL per animal

Reactions Reported:

Localised pain NOS Intervertebral disc disease Excessive chewing, licking and/or grooming Skin necrosis Reddening of the skin Burn Sedation prolonged Medication error NOS

Outcomes: Ongoing

Dog, Crossbred Canine/dog, Male, 10 year, 33.112 kilogram • Drug: MSK, Solution, Intramuscular, Dose: 0.70 mL per animal • Reactions: Urinary incontinence, Faecal incontinence, Tiredness (lethargy), Tremors, Loss of appetite… • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-054275
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 10.00 Year
Weight: 33.112 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Intramuscular
Form: Solution
Dose: 0.70 mL per animal

Reactions Reported:

Urinary incontinence Faecal incontinence Tiredness (lethargy) Tremors Loss of appetite Sedation prolonged Leucopenia NOS Lymphopenia Lack of efficacy - NOS Unable to walk Pyuria Haematuria Urinary tract infection

Outcomes: Ongoing

Dog, Griffon - French Wire-haired Pointing, Female, 2 year, 26.308 kilogram • Drug: MSK, Solution, Intramuscular, Dose: 0.20 mL per animal • Reactions: Tiredness (lethargy), Sedation, Decreased heart rate, Heart block NOS, Underdose… • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-052402
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 2.00 Year
Weight: 26.308 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Intramuscular
Form: Solution
Dose: 0.20 mL per animal

Reactions Reported:

Tiredness (lethargy) Sedation Decreased heart rate Heart block NOS Underdose Intentional misuse

Outcomes: Ongoing

Dog, Deutsche Dogge, Great Dane, Female, 4 year, 49.442 kilogram • Drug: MSK, Solution, Unknown • Reactions: Sleepiness - systemic disorder, Underdose • Outcome: Recovered/Normal

Report ID: USA-USFDACVM-2025-US-050969
Serious AE: No
Treated For AE: No
Sex: Female
Age: 4.00 Year
Weight: 49.442 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Solution

Reactions Reported:

Sleepiness - systemic disorder Underdose

Outcomes: Recovered/Normal

Cat, Domestic Shorthair, Male, 1.08 year, 5.216 kilogram • Drug: MSK, Unknown • Reactions: Seizure NOS, Open mouth breathing • Outcome: Recovered/Normal

Report ID: USA-USFDACVM-2025-US-049966
Serious AE: Yes
Treated For AE: No
Sex: Male
Age: 1.08 Year
Weight: 5.216 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

Seizure NOS Open mouth breathing

Outcomes: Recovered/Normal

Cat, Domestic Shorthair, Female, 4 year, 3.175 kilogram • Drug: MSK, Injection, solution, Other • Reactions: Injection site lump, Not eating, Pain NOS, Tiredness, Injection site sarcoma… • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-049334
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 4.00 Year
Weight: 3.175 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Other
Form: Injection, solution

Reactions Reported:

Injection site lump Not eating Pain NOS Tiredness Injection site sarcoma Limb amputation Abnormal radiograph finding

Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

No community reviews yet. Be the first to share your experience.

This medication has not been reviewed by a veterinarian yet.

Medical Disclaimer: The medication details provided on Roxee are for informational purposes only and are not a substitute for professional veterinary advice. Always consult your veterinarian about your pet's specific needs.

Atipamezole Hydrochloride

Add to My Pet's Meds

Reviewed / Updated / Sources

Pet Owner Quick Guide